CA-ATOMWISE
18.12.2020 12:02:07 CET | Business Wire | Press release
Atomwise , the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx , a recognized Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies. The collaboration will serve as the first introduction of Atomwise’s AtomNet® platform for AI-based drug discovery to a growing biotech innovation hub in Israel and is Atomwise’s second partnership with a global incubator hub.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201218005044/en/
As part of the strategic partnership, Atomwise will work closely with the FutuRx management team, investors and incubated portfolio companies to apply its AI technology to early-stage drug discovery projects. Atomwise and FutuRx have announced their first joint venture, A2i Therapeutics, with seed funding to leverage Atomwise’s AI platform to target a key protein involved in controlling the innate immune response and potentially a key immuno-oncology target. Atomwise’s AI platform, AtomNet®, can screen more than 16 billion compounds for potential hits in less than two days and has been used by researchers around the world to find hits on targets across numerous disease applications.
“FutuRx is excited to launch a new bio convergence company jointly with a world leader in AI-based drug discovery,” said Kinneret Savitzky, PhD, Chief Executive Officer of FutuRx. “Atomwise brings a legacy of collaboration and innovation in small-molecule drug discovery to our network of leading experts from multinational pharmaceutical companies and venture capital, “We are happy that our partnership with Atomwise will introduce its innovative AI platform for drug discovery to startups and emerging biotech companies in Israel.”
“The Israeli Innovation Authority leads Israel’s Bio-convergence strategy and is happy to have FutuRx once again join this effort together with its new partner Atomwise,” said Anya Eldan, VP of the Innovation Authority and Head of Startup Division. “Atomwise is at the forefront of AI-driven drug discovery, and this partnership with FutuRx will help pursue difficult disease targets and significantly boost the Israeli AI drug discovery and bio-convergence ecosystem.”
FutuRx now joins Atomwise’s growing network of investor and corporate partnerships, which today represents a collective deal value approaching $7 billion. Since its founding, Atomwise has built a strong portfolio of joint-venture companies and partnerships with emerging biotechnology, leading pharmaceutical and agrochemical companies.
In April 2020, Atomwise expanded its strategic partnership with Hansoh Pharma , a leading biopharmaceutical company in China, after successfully completing their first hit-discovery collaboration to identify hit compounds that are specific towards an intractable drug target. This announcement came on the heels of another expanded partnership earlier this year with Bayer to continue the development of two crop protection programs. As part of the strategic partnership, Atomwise is helping Bayer increase the speed and probability of discovering and developing new crop protection products through AI.
“We are excited to see Atomwise, a Leaps by Bayer portfolio company, collaborating with FutuRx on new frontiers for addressing our shared goal of curing and preventing cancer,” said Dr. Juergen Eckhardt, Head of Leaps by Bayer.
About FutuRx
FutuRx is the leading biotechnology incubator in Israel, established in 2014 by Johnson & Johnson Innovation (JJDC, Inc.), OrbiMed Israel Partners, and Takeda Pharmaceutical Company, through its venture group Takeda Ventures Inc., after winning a tender of the Israeli Innovation Authority. Recently Bayer has joined FutuRx as a strategic investor through its corporate venture LEAPS. The incubator is focused on innovative, early stage therapeutic technologies, and has established 23 companies to date. For more information about FutuRx, please visit https://www.futurx.co.il .
About Atomwise
Atomwise is revolutionizing how drugs are discovered with AI. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets across 775 collaborations spanning more than 250 partners around the world. Our portfolio of joint ventures and partnerships with leading pharmaceutical, agrochemical, and emerging biotechnology companies represents a collective deal value approaching $7 billion. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. Learn more at atomwise.com or follow @AtomwiseInc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201218005044/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phasecraft Joins DARPA’s Quantum Benchmarking Initiative3.3.2026 16:49:00 CET | Press release
Company will leverage its proprietary software and algorithms to inform verification and validation efforts Phasecraft, the world’s leading quantum algorithms company, today announced it has commenced work on the University of Maryland’s Applied Research Laboratory for Intelligence and Security’s (ARLIS) new contract to support the Defense Advanced Research Projects Agency’s (DARPA) ongoing Quantum Benchmarking Initiative (QBI). QBI’s goal is to assess if it is possible to achieve utility-scale quantum computing by 2033. Phasecraft joins the contract as a technical expert and will leverage its proprietary software and quantum algorithms to develop optimized estimates of resource requirements for quantum applications to inform the U.S. Government (USG) verification and validation efforts. Evaluating Progress Towards Quantum Utility While the cutting-edge quantum hardware selected for QBI inches closer to commercial utility, ultra-efficient quantum algorithms like those Phasecraft develo
Xsolla SDK Now Available for Game Developers Globally3.3.2026 15:48:00 CET | Press release
Backed by 20 years of Game Commerce Innovation, Xsolla SDK is a Platform Agnostic Software Development Kit that Game Developers Can Now Use to Seamlessly Expand Monetization Across Mobile, PC, and Web Xsolla, a global video game commerce company that has helped developers launch, grow, and monetize their games, today announced the availability of Xsolla SDK, a unified, cross-platform software development kit that consolidates the company's PC, mobile, and web monetization tools into a single download. Launching at GDC Festival of Games 2026, the Xsolla SDK introduces built-in Payments, Login, Catalog, and Offerwall integration for developers, enabling them to configure their pricing and inventory once and deploy across every supported platform with no reconfiguration required. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303075966/en/ Graphic: Xsolla Xsolla is building all the things to help developers monetize cross-pl
ZAPI GROUP to Showcase New Electrification Solutions at ConExpo/AGG 20263.3.2026 15:03:00 CET | Press release
Electrification leader demonstrates expanded low & high voltage capabilities at North America’s largest construction show ZAPI GROUP, a global leader in electrification, will demonstrate new solution capabilities within industrial vehicle electrification at ConExpo/AGG, taking place (March 3-7) in Las Vegas. As electrified construction equipment evolves to include larger, more demanding applications, the group has developed new higher-powered on-board DC/DC converters, inverters, electrical motors, and battery chargers to support those performance requirements, while combining additional utility functions within a compact form-factor. Featured solutions include: For motive power applications, a third-generation high-voltage inverter (ACH3) with customizable control software for enhanced performance, and a permanent magnet, electrical motor solution (IMI), with an integrated, liquid-cooled power-electronic inverter. On the battery-charging front, there will be new high-voltage, high-pow
Carta Launches CRM with Acquisition of ListAlpha3.3.2026 15:01:00 CET | Press release
Acquisition expands Carta’s AI-first ERP for private capital, creating an institutional-grade platform for deal teams and fundraising professionals to increase capital velocity Carta, the world’s first fully interconnected system for private capital, today announced it has acquired ListAlpha, the AI-powered CRM and relationship intelligence platform. The acquisition marks the launch of Carta CRM, a major expansion of the Carta ERP that further unifies front-to-back office workflows for the private markets. Private equity and venture capital firms have long operated in a fragmented way, keeping relationship context in siloed CRMs while fund performance data remains trapped in back-office ledgers. This information silo quietly erodes clarity for deal teams and GPs, slowing down teams and decreasing capital velocity. By integrating ListAlpha’s specialized CRM directly into the Carta ecosystem, firms can unify front-office intelligence with back-office execution on a single platform. Effec
Flexitech Chooses Rimini Street to Extend the Life of its SAP ECC, Accelerate Compliance and Fund Innovation3.3.2026 15:00:00 CET | Press release
Rimini Support™ for SAP helps French brake parts manufacturer avoid unwanted move to RISE with SAP, strengthen security and compliance readiness and reinvest freed capital into R&D and modernization initiatives Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced Flexitech, a French manufacturer of brake and cooling hose solutions for the global automotive industry, has selected Rimini Support™ for SAP to strengthen security, accelerate compliance readiness and free budget for innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303263951/en/ Flexitech Chooses Rimini Street to Extend the Life of its SAP ECC, Accelerate Compliance and Fund Innovation Rimini Support™ Enables Stability, Compliance and Strategic Reinvestment Flexitech relies on a stable SAP ECC 6 environment to support its w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom